Sign in
IMNN Stock Price, Chart, Stats & News
Imunon, Inc.
Save
4.49M
Market cap
–
Current P/E
16.78x
Forward P/E
IMNN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -159.43% |
ROE | -501.12% |
D/E | 0.27x |
Interest coverage ratio | – |
IMNN valuation
P/E | – |
P/S | – |
P/B | 1.96x |
P/CF | -0.55x |
P/FCF | -0.46x |
P/OCF | -0.55x |
PEG | -0.02x |
EV multiple | -0.80x |
About
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.
Similar securities
Based on sector and market capitalization
Report issue